Login to Your Account



Sonus, FDA Agree To Terms For Tocosol Paclitaxel SPA

By Aaron Lorenzo


Monday, July 11, 2005
Sonus Pharmaceuticals Inc. is moving forward with pivotal development plans for its lead product, Tocosol Paclitaxel, after completing a special protocol assessment for a single Phase III trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription